Low-volume, single-shot crystalloid cardioplegia is safe for isolated aortic valve replacement.
We report our experience with a low-volume (100 mL), single-shot crystalloid cardioplegia (Cardioplexol) in 61 consecutive patients undergoing isolated aortic valve replacement (AVR). Cardioplexol resulted in immediate cardiac arrest. Intraoperative courses were uneventful. Postoperative markers of myocardial damage, Troponin T and CK-MB levels, were low but steadily increased with longer cross-clamp time. Thirty-day mortality was 3% and all noncardiac. Cardioplexol not only simplifies and speeds up the procedure but also seems to be safe for patients undergoing AVR.
Clinic for Cardiac Surgery Basel, Heart Surgery Center Basel-Bern, Spitalstrasse 21, Basel, Switzerland. pmatt@uhbs.ch
Peter
P
Matt
Emilio
E
Arbeleaz
Goetz
G
Schwirtz
Thomas
T
Doebele
Friedrich
F
Eckstein
D000368:Aged; D001024:Aortic Valve Stenosis / Q000601:surgery*; D002314:Cardioplegic Solutions / Q000494:pharmacology*; D003080:Cold Temperature; D000077324:Crystalloid Solutions; D005260:Female; D005500:Follow-Up Studies; D006324:Heart Arrest, Induced / Q000379:methods*; D019918:Heart Valve Prosthesis Implantation / Q000379:methods*; D006801:Humans; D007036:Hypothermia, Induced; D007552:Isotonic Solutions / Q000494:pharmacology*; D008297:Male; D015532:Rehydration Solutions / Q000494:pharmacology; D012189:Retrospective Studies; D016896:Treatment Outcome
D002314:Cardioplegic Solutions; D000077324:Crystalloid Solutions; D007552:Isotonic Solutions; D015532:Rehydration Solutions